car- fil-zoe- mib
- Treatment of multiple myeloma in patients whose disease has relapsed or is refractory despite receiving ≥1 previous drug therapies (as monotherapy).
- Treatment of multiple myeloma in patients whose disease has relapsed or is refractory despite receiving 1–3 previous drug therapies (in combination with dexamethasone or lenalidomide + dexamethasone).
Acts as a proteasome inhibitor by binding to sites on the 20s proteasome. Has antiproliferative and proapoptotic activity.
Delayed progression of multiple myeloma.
Absorption: IV administration results in complete bioavailability.
Metabolism and Excretion: Rapidly and extensively metabolized by extrahepatic enzymes. Metabolites have no antineoplastic activity.
TIME/ACTION PROFILE (proteasome inhibition)
|IV||within 1 hr||unknown||>48 hr|
- Severe hepatic impairment;
- Patients ineligible for transplant (↑ risk of serious/fatal adverse reactions);
- OB: Pregnancy (may cause fetal harm)
- Lactation:Breastfeeding should be avoided.
Use Cautiously in:
- History of cardiovascular disease (may ↑ risk of adverse cardiovascular reactions, safe and effective use in patients with New York Heart Association Class III and IV HF, recent MI, or conduction abnormalities has not been established)
- Large tumor load (↑ risk of tumor lysis syndrome)
- Dehydration, diarrhea or electrolyte abnormalities (correct prior to treatment)
- Mild or moderate hepatic impairment (↓ dose)
- End stage renal disease
- Geri: ↑ risk of cardiovascular events;
- Rep: Women and men of reproductive potential (use effective contraception);
- Pedi: Safety and effectiveness not established.
Adverse Reactions/Side Effects
CNS: POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME (PRES), dizziness, fatigue, headache, insomnia, weakness
Resp: ACUTE RESPIRATORY DISTRESS SYNDROME, INTERSTITIAL LUNG DISEASE, PNEUMONITIS, cough, dyspnea
CV: HF, MYOCARDIAL ISCHEMIA/INFARCTION, VENOUS THROMBOEMBOLISM, hypertension, peripheral edema, pulmonary hypertension
GI: HEPATIC FAILURE, anorexia, constipation, diarrhea, hepatic toxicity, nausea
GU: acute renal failure
F and E: hypercalcemia, hypokalemia, hyponatremia, hypomagnesemia, hypophosphatemia
Hemat: THROMBOCYTOPENIA, THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP)/HEMOLYTIC UREMIC SYNDROME (HUS), anemia, leukopenia, lymphopenia
MS: back pain, chest wall pain, muscle spasms
Neuro: hypoesthesia, peripheral neuropathy
Misc: TUMOR LYSIS SYNDROME, fever/chills, infusion reactions
* CAPITALS indicate life-threatening.
Underline indicate most frequent.
Combination Therapy with Lenalidomide + Dexamethasone
IV: (Adults) Cycle 1– 20 mg/m2 daily for 2 days (Days 1 and 2); if tolerated, ↑ dose to 27 mg/m2 on days 8, 9, 15, and 16 of a 28–day treatment cycle. Cycles 2–12– 27 mg/m2 on days 1, 2, 8, 9, 15, and 16 of a 28–day treatment cycle; Cycles 13–18– 27 mg/m2 on days 1, 2, 15, and 16 of a 28–day treatment cycle. Cycles 19 and subsequent cycles– Continue lenalidomide and dexamethasone (without carfilzomib) until unacceptable toxicity or disease progression.
Combination Therapy with Dexamethasone
IV: (Adults) Cycle 1– 20 mg/m2 daily for 2 days (Days 1 and 2); if tolerated, ↑ dose to 56 mg/m2 on days 8, 9, 15, and 16 of a 28–day treatment cycle. Cycle 2 and subsequent cycles– 56 mg/m2 on days 1, 2, 8, 9, 15, and 16 of a 28–day treatment cycle. Continue both carfilzomib and dexamethasone until unacceptable toxicity or disease progression.
20/27 mg/m2 regimen
IV: (Adults) Cycle 1– 20 mg/m2 daily for 2 days (Days 1 and 2); if tolerated, ↑ dose to 27 mg/m2 on days 8, 9, 15, and 16 of a 28–day treatment cycle. Cycles 2–12– 27 mg/m2 on days 1, 2, 8, 9, 15, and 16 of a 28–day treatment cycle; Cycle 13 and subsequent cycles– 27 mg/m2 on days 1, 2, 15, and 16 of a 28–day treatment cycle. Continue carfilzomib until unacceptable toxicity or disease progression.
20/56 mg/m2 regimen
IV: (Adults) Cycle 1– 20 mg/m2 daily for 2 days (Days 1 and 2); if tolerated, ↑ dose to 56 mg/m2 on days 8, 9, 15, and 16 of a 28–day treatment cycle. Cycles 2–12– 56 mg/m2 on days 1, 2, 8, 9, 15, and 16 of a 28–day treatment cycle; Cycle 13 and subsequent cycles– 56 mg/m2 on days 1, 2, 15, and 16 of a 28–day treatment cycle. Continue carfilzomib until unacceptable toxicity or disease progression.
IV: (Adults) Hemodialysis– Administer dose after hemodialysis.
IV: (Adults) Mild or moderate hepatic impairment– ↓ dose by 25%.
Lyophilized powder for IV injection (requires reconstitution): 10 mg/vial , 30 mg/vial, 60 mg/vial
- Maintain hydration status throughout therapy. Monitor for dehydration and fluid overload, especially in patients with or at risk for HF.
- Monitor for cardiac complications (BP, new or worsening HF, decreased left ventricular function, myocardial ischemia). Withhold dose for Grade 3 or 4 cardiac events until recovery. Consider restarting at a reduced dose. If tolerated, dose may be escalated to previous dose.
- Assess for pulmonary hypertension with cardiac imaging. Withhold dose until resolved or returned to baseline. Consider restarting based on risk/benefit ratio. May use a reduced dose and escalate as tolerated.
- Monitor for dyspnea frequently during therapy. Interrupt therapy until symptoms resolved; consider restarting with one dose level reduction and increase as tolerated. If drug-induced pulmonary toxicity occurs, discontinue carfilzomib.
- Assess for sensory and motor peripheral neuropathy periodically during therapy. If Grade 3 or 4 occurs, withhold dose until resolved or returned to baseline. Restart with prior or reduced dose, may escalate if tolerated.
- Monitor for signs and symptoms of tumor lysis syndrome (hyperuricemia, hyperkalemia, hyperphosphatemia, hypocalcemia) during therapy. Consider uric acid lowering drugs in patients at risk. Manage promptly; may require discontinuation.
- Monitor for infusion reactions. May occur immediately or up to 24 hrs after administration. Premedicate with dexamethasone prophylactically.
- Assess for signs and symptoms of thrombotic thrombocytopenic purpura /hemolytic uremic syndrome (weakness, confusion or coma, abdominal pain, nausea, vomiting, diarrhea, arrhythmias). Discontinue therapy if symptoms occur.
- Monitor for signs and symptoms of posterior reversible encephalopathy syndrome (PRES) (seizure, headache, lethargy, confusion, blindness, altered consciousness, other visual and neurological disturbances, hypertension). Determined with MRI. Discontinue if symptoms occur.
Lab Test Considerations:
Monitor CBC and platelet count frequently during therapy. Nadir of thrombocytopenia occurs around Day 8 of 28–day cycle and recovery to baseline by start of next 28–day cycle. If ANC <0.5 x 109 /L, withhold dose. If recovered to ≥0.5 x 109 /L, continue at the same dose. For subsequent drops to <0.5 x 109 /L, follow recommendations above and consider 1 dose level reduction when restarting carfilzomib. If ANC <0.5 x 109 /L and an oral temperature >38.5°C. or two consecutive readings of >38.0° for more than 2 hrs, withhold dose. If ANC returns to baseline and fever resolves, resume therapy at same dose. If platelets <10 x 109 /L or evidence of bleeding with thrombocytopenia, withhold dose. If recovered to ≥10 x 109 /L and/or bleeding is controlled, continue at same dose. For subsequent drops to <10 x 109 /L, follow recommendations above and consider 1 dose level reduction when restarting carfilzomib.
- Monitor liver enzymes frequently during therapy. May cause ↑ serum transaminases and bilirubin. If Grade 3 or 4 ↑ of transaminases, bilirubin, or other liver abnormalities withhold dose until resolved or return to baseline. May be restarted at a reduced dose with frequently liver function monitoring; may escalate dose if tolerated.
- Monitor renal function frequently during therapy. If serum creatinine ≥2 times baseline or creatinine clearance <15 mL/min, or creatinine clearance ↓ ≤50% of baseline, or need for dialysis, withhold dose and continue monitoring. If ↓ renal function attributable to carfilzomib, resume when renal function has recovered to within 25% of baseline; start at 1 dose level reduction. If not attributable to carfilzomib, dosing may be resumed at discretion of physician. For patients on dialysis receiving carfilzomib, administer dose after dialysis procedure.
- Monitor serum potassium periodically during therapy. May cause hyperglycemia, hypercalcemia, hypophosphatemia, and hyponatremia.
- Hydrate patient to reduce risk of renal toxicity and tumor lysis syndrome. At least 48 hrs prior to Cycle 1, Day 1, administer oral fluids (30 mL per kg) and IV fluids (250 mL to 500 mL of IV fluid prior to each dose in Cycle 1). Give an additional 250 mL to 500 mL of IV fluids following administration, if needed. Continue oral and/or IV hydration, as needed, in subsequent cycles.
- For monotherapy, premedicate with dexamethasone 4 mg PO or IV at least 30 minutes but no >4 hours prior to all doses during Cycle 1 to reduce the incidence and severity of infusion reactions. For combination with lenalidomide, premedicate with dexamethasone 40 mg PO or IV at least 30 minutes but no >4 hours prior to doses on Days 1, 8, 15, and 22 during each cycle to reduce the incidence and severity of infusion reactions. Reinstate if symptoms develop during subsequent cycles.
- Thromboprophylaxis regimen should be used with combination therapy with dexamethasone with or without lenalidomide.
- Use antiviral prophylaxis to decrease risk of herpes zoster reactivation.
- Intermittent Infusion: Reconstitute each vial by injecting 29 mL Sterile Water for injection directed onto inside wall of vial to minimize foaming. Swirl gently or invert slowly for 1 min or until complete dissolution of powder; do not shake. If foaming occurs, allow solution to rest for 2–5 min until foaming subsides. Solution should be clear and colorless; do not administer solutions that are discolored or contain particulate matter. Diluent: Withdraw calculated dose from vial and dilute in 50 or 100 mL D5W. Vial may exceed required dose; calculate dose carefully to prevent overdosing. Reconstituted solution is stable at room temperature for 4 hrs and 24 hrs if refrigerated. Discard unused portion.
- Rate: For carflizomib in combination with lenalidomide and dexamethasone, infuse over 10 min. For carflizomib in combination with dexamethasone, infuse over 30 min. For monotherapy with 20/27 mg/m2 regimen, infuse over 10 min. For monotherapy with 20/27 mg/m2 regimen, infuse over 30 min. Do not administer as a bolus. Flush line with 0.9% NaCl or D5W prior to and following administration.
- Y-Site IncompatibilityDo not mix with or infuse with other medications.
- Explain purpose of medication to patient.
- Advise patient to notify health care professional immediately if infusion reactions (fever, chills, rigors, arthralgia, myalgia, facial flushing, facial edema, vomiting, weakness, shortness of breath, hypotension, syncope, chest tightness, chest pain, cough, swelling of feet or legs) occur.
- May cause fatigue, dizziness, fainting, and drop in BP. Caution patient to avoid driving or other activities requiring alertness until response to medication is known.
- Advise patient to maintain hydration status during therapy; may cause vomiting and/or diarrhea.
- Advise patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications.
- Rep: Advise female patients of reproductive potential to use effective contraception during therapy and for at least 30 days following therapy and to avoid breastfeeding. Avoid hormonal contraceptives during combination therapy to prevent increased risk of thrombosis. Advise male patients to use effective contraception during and for at least 90 days after last dose.
Slowed progression of multiple myeloma.
Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Learn more.